Study S001313

A Phase 3, Randomized, Open-label, Parallel-group, Multicenter, Controlled Study to Evaluate Efficacy and Safety of Semaglutide Injection (HD1916) vs. Ozempic® as add-on to Metformin in Patients With Type 2 Diabetics Mellitus

ClinicalTrials.gov record

Registration

Registration: NCT06161844
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 506
Start: 2024-02-23
Primary completion: 2025-05-14
Lead sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:semaglutide injection (HD1916); DRUG:Ozempic®
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Change from baseline to week 32 in glycosylated haemoglobin (HbA1c) [Week 32]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.